← All trials
NCT06435429
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 13, 2024
- Primary completion
- Sep 26, 2028
- Completion date
- Nov 26, 2031
- First posted
- May 30, 2024
- Last posted
- Aug 27, 2024
- Enrollment
- 550
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jazz PharmaceuticalsLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.